- Home
- MKSI vs RYTM Comparison
MKSI vs RYTM Comparison
Compare MKSI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKSI
- RYTM
- Stock Information
- Founded
- MKSI 1961
- RYTM 2008
- Country
- MKSI United States
- RYTM United States
- Employees
- MKSI N/A
- RYTM N/A
- Industry
- MKSI Industrial Machinery/Components
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MKSI Industrials
- RYTM Health Care
- Exchange
- MKSI Nasdaq
- RYTM Nasdaq
- Market Cap
- MKSI 7.1B
- RYTM 6.4B
- IPO Year
- MKSI 1999
- RYTM 2017
- Fundamental
- Price
- MKSI $136.68
- RYTM $110.20
- Analyst Decision
- MKSI Buy
- RYTM Strong Buy
- Analyst Count
- MKSI 10
- RYTM 13
- Target Price
- MKSI $128.70
- RYTM $110.38
- AVG Volume (30 Days)
- MKSI 1.1M
- RYTM 578.6K
- Earning Date
- MKSI 11-05-2025
- RYTM 11-04-2025
- Dividend Yield
- MKSI 0.65%
- RYTM N/A
- EPS Growth
- MKSI 3206.74
- RYTM N/A
- EPS
- MKSI 3.95
- RYTM N/A
- Revenue
- MKSI $3,741,000,000.00
- RYTM $156,287,000.00
- Revenue This Year
- MKSI $8.81
- RYTM $46.14
- Revenue Next Year
- MKSI $5.79
- RYTM $63.37
- P/E Ratio
- MKSI $34.49
- RYTM N/A
- Revenue Growth
- MKSI 4.50
- RYTM 53.55
- 52 Week Low
- MKSI $54.84
- RYTM $45.91
- 52 Week High
- MKSI $142.20
- RYTM $113.91
- Technical
- Relative Strength Index (RSI)
- MKSI 60.96
- RYTM 69.35
- Support Level
- MKSI $127.45
- RYTM $97.97
- Resistance Level
- MKSI $139.10
- RYTM $113.91
- Average True Range (ATR)
- MKSI 5.99
- RYTM 3.77
- MACD
- MKSI -0.35
- RYTM 1.20
- Stochastic Oscillator
- MKSI 73.59
- RYTM 79.43
About MKSI MKS Instruments Inc.
MKS Inc formerly, MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others, used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.